ReviewCureus2026
Undifferentiated Nasopharyngeal Carcinoma in Low- and Middle-Income Countries: Clinical, Molecular, and Health-System-Related Challenges.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Undifferentiated nasopharyngeal carcinoma (UNPC) is a virally driven malignancy that disproportionately impacts low- and middle-income countries (LMICs). Although advances in MRI, intensity-modulated radiotherapy (IMRT), and plasma Epstein-Barr virus (EBV) DNA testing have substantially improved outcomes in well-resourced settings, significant diagnostic and therapeutic gaps remain across endemic LMIC regions. More than 70% of global UNPC cases occur in these settings, where delayed diagnosis, limited access to MRI and PET-CT, restricted availability of EBV DNA testing, and fragile radiotherapy capacity contribute to advanced-stage presentation and poorer survival. Molecular and proteomic analyses have identified clinically relevant UNPC subgroups, but their translation into routine care is constrained by inadequate laboratory infrastructure. Systemic therapy delivery is often compromised by drug shortages, logistical challenges, and financial barriers, while substantial psychosocial distress further undermines treatment adherence. UNPC outcomes reflect an interplay between tumor biology and broader health system inequities. Strengthening referral pathways, decentralizing diagnostic services, scaling EBV DNA testing, reinforcing radiotherapy infrastructure, and integrating supportive care represent feasible, high-impact strategies to reduce survival disparities in LMICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.